股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金斯瑞生物科技股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01548 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.001 | USD | | 5,000,000 | 本月底法 ...

Group 1 - The core viewpoint of the news is that Hong Kong's innovative drug concept stocks experienced a collective rise, indicating positive market sentiment in the pharmaceutical sector [1] Group 2 - Jingtai Holdings (02228) saw an increase of 6.13%, with a latest price of 10.040 and a total market capitalization of 43.206 billion [2] - Hengrui Medicine (01276) rose by 4.63%, with a latest price of 74.550 and a total market capitalization of 494.803 billion [2] - SiHuan Pharmaceutical (00460) increased by 4.07%, with a latest price of 1.280 and a total market capitalization of 11.707 billion [2] - Innovent Biologics (01801) experienced a rise of 3.34%, with a latest price of 78.800 and a total market capitalization of 135.599 billion [2] - WuXi Biologics (02269) increased by 3.18%, with a latest price of 32.440 and a total market capitalization of 133.916 billion [2] - China National Pharmaceutical Group (01177) rose by 3.07%, with a latest price of 6.370 and a total market capitalization of 119.506 billion [2] - BeiGene (06160) saw an increase of 2.68%, with a latest price of 184.100 and a total market capitalization of 283.639 billion [2] - Kingstar Bio (01548) rose by 2.66%, with a latest price of 12.750 and a total market capitalization of 27.874 billion [2] - Genscript Biotech (01952) increased by 2.49%, with a latest price of 37.900 and a total market capitalization of 13.4 billion [2] - WuXi AppTec (02359) saw a rise of 2.13%, with a latest price of 100.800 and a total market capitalization of 300.763 billion [2]

Group 1 - Hong Kong biopharmaceutical stocks weakened during trading on December 30, with Genscript Biotech falling nearly 4% [1] - Fuhong Hanlin declined by nearly 3%, while Kelun-Biotech dropped over 2% [1] - Other stocks such as CanSino Biologics, Rongchang Biologics, and Kanyin Biologics also experienced declines of over 1.5% [1]

Market Overview - The US CPI annual rate decline has led to a rise in US stocks, boosting risk market sentiment [1] - The Hang Seng Index opened higher and closed up 0.75%, with the Hang Seng China Enterprises Index and Hang Seng Tech Index rising by 0.68% and 1.12% respectively [1][2] Sector Performance - Major technology stocks saw collective gains, with Tencent up 1.49%, Kuaishou up 1.45%, and Meituan up 1.28% [4] - Pharmaceutical stocks were active, with WuXi AppTec and other related stocks rising [2] - Gaming stocks continued to rise, with MGM China leading with a 6.6% increase [2][5] - AI-driven demand boosted optical fiber and cable stocks, with Yangtze Optical Fiber rising 12% [2] - Automotive, wind power, education, photovoltaic, insurance, and Apple-related stocks also experienced gains [2] Notable Stock Movements - Xpeng Motors rose 7.65%, Horizon Robotics up 7.04%, and Li Auto up 3.81% [4][10] - Electronic cigarette stocks saw significant increases, with China Tobacco Hong Kong up 6.68% [5] - Chinese brokerage stocks rose, with China International Capital Corporation up over 4% [7] - Intelligent driving concept stocks surged, with Youjia Innovation up 31.22% [8] Weak Performers - Heavy machinery stocks faced declines, with China National Heavy Duty Truck Group down over 6% [13] - Gold and precious metal stocks were weak, with several companies experiencing declines of over 2% [16] - Oil stocks also fell, with China Petroleum & Chemical Corporation down 1.52% [15] Capital Flows - Southbound funds recorded a net purchase of HKD 3.371 billion, with net selling from Shanghai-Hong Kong Stock Connect and net buying from Shenzhen-Hong Kong Stock Connect [18] Market Outlook - CITIC Securities suggests that after a strong performance in September, Hong Kong stocks are undergoing a mid-term adjustment, with quality assets entering a high-value zone [18]

Core Viewpoint - Kingsray Biotechnology (01548.HK) announced the grant of a total of 36,314 shares as rewards to two directors, subject to acceptance and compliance with the terms and conditions of the 2019 Restricted Share Unit Plan [1] Summary by Category - **Company Actions** - The company has granted a total of 36,314 shares as rewards to two directors [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced the grant of a total of 36,300 shares as rewards to two directors, subject to acceptance and compliance with the terms and conditions of the 2019 Restricted Share Unit Plan [1] Group 1 - The company is set to issue 36,300 shares as part of a reward program for its directors [1] - The share grant is contingent upon acceptance and adherence to the 2019 Restricted Share Unit Plan [1]

Core Viewpoint - Kingsray Biotechnology (01548) announced the grant of a total of 36,300 shares as rewards to two directors, pending acceptance and compliance with the terms and conditions of the 2019 Restricted Share Unit Plan [1] Group 1 - The company is set to issue 36,300 shares as part of a reward program for its directors [1] - The share grant is contingent upon acceptance and adherence to the existing 2019 Restricted Share Unit Plan [1]

格隆汇12月16日丨金斯瑞生物科技(01548.HK)发布公告，2025年12月15日，公司向两名董事授出合共 36,314股股份奖励，惟待接纳及须遵守2019年限制性股份单位计划的条款及条件。其中，(a)18,157股限 制性股份单位被授予公司独立非执行董事John Quelch博士；及(b)18,157股限制性股份单位被授予公司独 立非执行董事Ross Grossman博士。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 Genscript Biotech Corporation （於開曼群島註冊成立的有限公司） （股份代號：1548） 授出股份獎勵 本公告由本公司董事會根據上市規則17.06A條、17.06B條及17.06C條作出。除本公告另 有界定者外，本公告所用專有詞彙與通函所界定者具有相同涵義。 授予A的日期： 2025年12月15日 授出股份獎勵數目： 36,314股限制性股份單位 董事承授人： (a) 18,157股限制性股份單位被授予本公司獨立非執行董事 John Quelch博士；及 (b) 18,157股限制性股份單位被授予本公司獨立非執行董事 Ross Grossman博士。 股份市價： 於授予A的日期，股份於聯交所的收市價為每股股份12.86港 元。 歸屬期： 根據授予A及2019年限制性股份單位計劃的條款，授予董事 承授人的限制性股份單位將在合共約3年的歸屬期（即從授 予A的日期至最後歸屬日期期間 ...

發行人剛在本網站英文版面發布一項公告，相應中文版本或會／或不會在本版面發布。 ...